Life Sciences Scoop | May 2024
Warman O'Brien
Global Life Sciences Recruitment Partner across the USA, UK, Europe and APAC
Welcome to our May newsletter. As the Life Sciences industry continues its remarkable progress, we're delighted to present some insightful career updates in this month's edition. Following a period of market correction last year, we're now seeing signs of gradual stabilisation, which translates into exciting new opportunities within various areas.
This month's newsletter brings you:
You can subscribe to our monthly newsletter and get it straight to your inbox, to make sure you don't miss it.
Jobs of the month
Clinical | USA
Both roles
Oncology: Fully home-based preferred or Non-Oncology Therapeutics: Hybrid/on-site preferred
Biostatistics
UK & Europe
USA & Canada
Medical Affairs
USA & Canada
UK &? Europe
Scientific
Statistical Programming
领英推荐
UK & Europe
USA & Canada
Clinical Data Management
What to Read (and Watch)
Overview of the Medical Device Market
Our new fireside chat video with an industry veteran Dan Mans , who brings 30 years of expertise in med-tech to the conversation. In this conversation:
? The challenges medical device companies faced in 2023
? Breakthrough technologies shaping the US market, including noteworthy mergers and acquisitions
? Inspiring examples of successful med-tech companies and predictions for the future of the market
7 Billion-Dollar Oncology M&As from Q1
It's been a big year so far for M&A in the life sciences market, and the general attitudes and feeling in the industry are a far cry from last years layoffs and liquidations. There is still a way to go in terms of recovery, and we are still far away from the highs of the COVID market, but it's getting better!
Below, BioSpace have compiled some of the biggest M&As of the year so far, all worth over a billion dollars. Having 7 multi billion dollar deals in Q1 is a sure step in the right direction for the market and will hopefully lead to some great new treatments hitting the market soon!
Conor Burke, our Clinical Recruitment Consultant, commented: “AbbVie were the biggest spenders, with $10.1 billion spent on ImmunoGen, Inc., while Bristol Myers Squibb came both second and third in deal size, spending a combined $8.9 billion on Mirati Therapeutics and RayzeBio. Other big spenders in the included AstraZeneca, Johnson & Johnson and Novartis, all spending over a billion.
This investment shows a change in opinions in the market, with companies taking bigger risks and investing more in new products, signaling a change of attitudes and hopefully a change in the trends of the recruitment market soon!”
Who are Warman O’Brien?
Warman O'Brien is a global Life Sciences Recruitment partner. We're proud to say that we have a 90% success rate of CV-to-interview matches, and our partnerships with pioneering?Biotech, Pharma, and CROs across the USA, Canada, UK, and Europe. We recruit top talent across multiple functional areas, including Biometrics, Data Science, Quality Assurance, Regulatory Affairs, Clinical Research, Discovery Sciences, and Medical.
Register on our website and be the first to apply for the new job offerings.